October 21, 2024​

​

MONTEVIDEO, Uruguay – Kinzbio, a pioneering clinical and commercial-stage biotech company specializing in phage-based precision antimicrobials, announces the strategic appointment of Dr. Patrick Guye as its first independent Non-Executive Director. This announcement comes against the backdrop of a dire global health crisis: Antimicrobial Resistance (AMR), which was associated with 4.7 million deaths globally in 2021 alone. With projections estimating AMR to be the leading cause of death by 2050, resulting in approximately 40 million accumulated deaths, Kinzbio’s mission to develop innovative treatments against antibiotic-resistant infections has never been more critical.

​

Dr. Guye joins the company with a robust background in microbiology and strategic business management, poised to drive Kinzbio's growth and expansion during this pivotal time. His deep expertise in infection biology, extensive experience in therapeutic development, product management, and biomedical B2B services, coupled with a proven track record of guiding startups to success, align perfectly with Kinzbio’s ambitious goals.

 

In his current role as CEO of Trilliome, Dr. Guye has demonstrated exceptional leadership in driving innovation in microbiome-modulating nutraceuticals, an expertise that complements Kinzbio's focus on combating AMR. His career is marked by significant achievements in financial strategy and fundraising, securing substantial investments for life sciences ventures and steering companies towards operational excellence and market readiness.

​

Throughout his career, Dr. Guye has excelled in financial strategy and fundraising, securing investments from seed funding to Series C and special financing instruments totaling tens of millions of dollars. His expertise in due diligence and portfolio strategy has been instrumental for venture capital and private equity firms investing in the life sciences sector.

​

Previously, as Chief Operating Officer at Rejuveron, he led initiatives to ready the company for an IPO by enhancing operational excellence and ensuring regulatory compliance. As Chief Scientific Officer at InSphero AG, he oversaw key departments, optimized organizational structures, and significantly boosted annual revenues through strategic partnerships and innovative service expansions.

​

His earlier tenure at Sanofi in Germany provided insights into large pharmaceutical operations. At the same time, his work at MIT and Princeton University focused on synthetic biology and therapeutic development within entrepreneurial settings.

​

In addition to his executive roles, Dr. Guye serves as an expert for Innosuisse. He is an active member of professional organizations, including the ISSCR, SECA (Swiss Private Equity & Corporate Finance Association), and SwissHLG (Healthcare Licensing & M&A), reflecting his commitment to advancing the biotechnology sector.

​

Patrick Guye, independent Non-Executive Director of Kinzbio, said: “I am thrilled to join forces with the exceptional team at Kinzbio to drive our mission forward. Our goal is to broaden the application of our phage-based precision medicine pipeline, targeting the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria”.

​

Gregorio Iraola, CEO of Kinzbio, added: “Dr. Guye’s appointment marks a significant step for Kinzbio as we advance our innovative solutions in the global fight against AMR”, stated Gregorio Iraola, CEO of Kinzbio. “His strategic vision and industry expertise will be invaluable as we expand our reach and impact”.

 

​​

​

​

About Kinzbio

 

Kinzbio is a biotech company developing and commercializing phage-based precision antimicrobials to treat and prevent antibiotic-resistant infections. Since its incorporation in 2021, Kinzbio has developed an innovative technology platform enabling the discovery of previously ‘unculturable’ phages with bigger genomes and advantageous biological properties. Armed with these unique phages and proprietary methods for their genomic characterization, propagation and biomanufacturing, Kinzbio is pursuing a business-to-business model across the Latin American region and internationally to make phage therapy accessible to patients suffering from acute and chronic bacterial infections caused by antimicrobial-resistant pathogens.

​

​

​

​​

​

​

​

​

​

​

​

​

For more information, please visit www.kinzbio.com or contact info@kinzbio.com.